Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2025)
Vanda Pharmaceuticals (VNDA) reported Share-based Compensation of $915000.0 for Q1 2025, down 74.47% on a YoY basis from $3.6 million in Q1 2024, and up 113.93% sequentially from -$6.6 million in Q3 2024.
Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2025) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 16 years of Share-based Compensation data on file, last reported at $915000.0 in Q1 2025.
- For the quarter ending Q1 2025, Share-based Compensation fell 74.47% year-over-year to $915000.0; the trailing twelve-month figure through Dec 2025 stood at $915000.0 (changed N/A YoY), and the FY2025 full-year result was $915000.0, changed N/A from the prior year.
- Share-based Compensation rose to $915000.0 in Q1 2025, from -$6.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.8 million in Q1 2022 to a low of -$10.8 million in Q4 2023.
- A 5-year average of $2.0 million and a median of $3.8 million in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation grew 26.03% in 2021 and plunged 384.62% in 2023, its largest moves.
- Tracing VNDA's Share-based Compensation over 5 years: stood at $3.8 million in 2021, then advanced by 0.24% to $3.8 million in 2022, then sank by 384.62% to -$10.8 million in 2023, then soared by 38.98% to -$6.6 million in 2024, then surged by 113.93% to $915000.0 in 2025.
- Business Quant data shows VNDA's Share-based Compensation at $915000.0 in Q1 2025, -$6.6 million in Q3 2024, and $3.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 915,000.00 |
| Mar 31, 2025 | 915,000.00 |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | -10.77 Mn |
| Dec 31, 2023 | -10.77 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 4.35 Mn |
| Mar 31, 2023 | 4.35 Mn |
| Dec 31, 2022 | 3.78 Mn |
| Dec 31, 2022 | 3.78 Mn |
| Sep 30, 2022 | 3.89 Mn |
| Sep 30, 2022 | 3.89 Mn |